Healthcare · NSE: ADVENZYMES
Advanced Enzyme Technologies
Q2 FY27 earnings and concall highlights
Q2 FY27 earnings call · Guided by management
Call held 3 Nov 2026 · Read the filing on NSEFiling
- M.Cap
- ₹3,122Cr
- P/E
- 18.3×
- 1Y return
- −14.84%
- From 52W high
- −33.0%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · consolidated · ₹ Cr
| Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 215 | 185 | +16.2% | 190 | +13.0% |
| EBITDA | 72 | 60 | +20.1% | 51 | +41.5% |
| EBITDA margin | 33.6% | 32.5% | +107 bps | 26.9% | +677 bps |
| PBTProfit before tax | 69 | 60 | +15.5% | 54 | +28.5% |
| Net profit | 48 | 43 | +11.5% | 37 | +30.3% |
| EPS (₹) | 4.32 | 3.87 | +11.6% | 3.31 | +30.5% |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.
Guidance
Management expects growth and stronger performance for the rest of the year
Mukund Kabra · Whole Time Director · p. 4
Management expects growth and stronger performance for the rest of the year
“We anticipate this sustainable growth and stronger performance throughout the rest of the year.”
Management aims for lower double-digit revenue growth; no exact number
Mukund Kabra · Whole Time Director · Q&A · p. 8
Management aims for lower double-digit revenue growth; no exact number
“But I cannot give you the exact number. Yes, that is what we were talking about is a double-digit growth, lower double-digit growth. That is where we are aiming for.”
Company intends to grow by lower-mid to mid double digits over the longer run
Mukund Kabra · Whole Time Director · Q&A · p. 13
Company intends to grow by lower-mid to mid double digits over the longer run
“This year, I would say that overall, we -- and for a longer run, we intend to grow by double digits, mid-level of double digits or lower mid-level of double digit. And that's what we plan.”
More figures from the call
“At this point of time, I won't say that how long it will take, maybe 1 quarter or 2 quarters. But what we can say is there is a lot of good traction, which is coming up again.”
“I would say it will be very approximate. But if you want the number, maybe around 7%, 8% is coming from the new products.”
In short
- 01Q2 FY27 revenue was INR2,145 million, up 16% year-on-year and 12% sequentially.
- 02EBITDA margin was 34% in Q2; management keeps its 30% to 32% EBITDA margin guidance.
- 03Management aims for lower double-digit revenue growth, and mid double-digit over the longer run.
- 04The buyback was completed, with 2.41 million shares acquired; cash is about INR610 crore.
- 05Capex plan for the year is unchanged; around INR52 crore spent so far.
- 06US demand was dull in the first two quarters; management expects a pick-up towards year-end.
- 07About INR7.5 crore of deferred sales is carried into the next quarter.
Capacity
SciTech: SciTech growth broad-based; more shifts raised production capacity and efficiency
Mukund Kabra · Whole Time Director · Q&A · p. 8
SciTech: SciTech growth broad-based; more shifts raised production capacity and efficiency
“It's more broad-based. We increased a lot of efficiencies out there. We increased some shift working out there. That is where like we increase the production capacity.”
Segments
Human Healthcare: Human Healthcare Q2 revenue INR1,285 million, up 6% year-on-year
Mukund Kabra · Whole Time Director · p. 4
Human Healthcare: Human Healthcare Q2 revenue INR1,285 million, up 6% year-on-year
“Revenues for quarter 2 financial year '27 stood at INR1,285 million, reflecting a 6% Y-o-Y growth and 11% sequential increase.”
Human Healthcare: Human Healthcare growth came from Pharma/API, Biocatalysis and Nutrition; flat on YTD basis
Mukund Kabra · Whole Time Director · p. 5
Human Healthcare: Human Healthcare growth came from Pharma/API, Biocatalysis and Nutrition; flat on YTD basis
“This growth was primarily attributable to improved sales in the Pharma/API business, Biocatalysis and Nutrition business. Human Healthcare business remained unchanged on YTD basis.”
Animal Healthcare: Animal Healthcare Q2 revenue INR265 million
₹26.5CrMukund Kabra · Whole Time Director · p. 5
Animal Healthcare: Animal Healthcare Q2 revenue INR265 million
₹26.5Cr“Moving to Animal Healthcare. Revenue stood at INR265 million”
Bio-Processing: Bio-Processing Q2 revenue INR365 million, up 43% year-on-year; H1 up 37%
Mukund Kabra · Whole Time Director · p. 5
Bio-Processing: Bio-Processing Q2 revenue INR365 million, up 43% year-on-year; H1 up 37%
“The segment reported revenues of INR365 million, delivering a strong 43% year-on-year growth, 19% sequential increase and 37% growth in the first half of the fiscal.”
Specialized Manufacturing: Specialized Manufacturing Q2 revenue INR231 million, up 25% year-on-year; H1 up 32%
Mukund Kabra · Whole Time Director · p. 5
Specialized Manufacturing: Specialized Manufacturing Q2 revenue INR231 million, up 25% year-on-year; H1 up 32%
“Lastly, Specialized Manufacturing reported revenues of INR231 million, registering a healthy 25% year-on-year growth, 15% increase over the previous quarter and 32% growth in the first half of the current fiscal.”
Demand
Top-10 customers were about 26% of Q2 revenue, against 27% a year ago
Beni Rauka · Group Chief Financial Officer · p. 6
Top-10 customers were about 26% of Q2 revenue, against 27% a year ago
“Our top-10 customers contribute about 26% in quarter 2 of this year as compared to 27% in quarter 2 of last year.”
U.S. market: US market was dull in first two quarters; expected to pick up towards year-end
Mukund Kabra · Whole Time Director · Q&A · p. 7
U.S. market: US market was dull in first two quarters; expected to pick up towards year-end
“there was some kind of a dullness which was there, which we can see in the first 2 quarters because of all the global things, however, it is moving. But we expect it to pick up as we move on towards the year-end.”
Animal Healthcare, Food Processing, Specialized Manufacturing: Segment growth from new customers, new products and new geographies
Mukund Kabra · Whole Time Director · Q&A · p. 10
Animal Healthcare, Food Processing, Specialized Manufacturing: Segment growth from new customers, new products and new geographies
“So here, if you ask me it's more with increasing the customer base as well and developing the new products as well and approaching different geographies as well.”
U.S. market: Existing US clients not growing fast; company adding new customers
Mukund Kabra · Whole Time Director · Q&A · p. 12
U.S. market: Existing US clients not growing fast; company adding new customers
“Particularly, if you ask me clients are growing, I don't see the existing clients are growing very rapidly at a very fast pace as of now. And we are also now working on to add different, different customers in different areas.”
Margins and costs
Q2 EBITDA margin 34%, against 33% a year ago and 28% in Q1
Mukund Kabra · Whole Time Director · p. 4
Q2 EBITDA margin 34%, against 33% a year ago and 28% in Q1
“Consequently, the EBITDA margin stood at 34% compared to 33% in quarter 2 financial year '26 and 28% in quarter 1 financial year '27.”
Power, fuel and raw material costs stayed elevated; efficiencies offset them
Mukund Kabra · Whole Time Director · p. 4
Power, fuel and raw material costs stayed elevated; efficiencies offset them
“Although the input costs like power and fuel and raw material remained elevated during the quarter, but our focus on operational efficiencies eliminated the risk and delivered robust margins.”
PAT margin 24% in Q2 and 22% in H1 FY27
Mukund Kabra · Whole Time Director · p. 4
PAT margin 24% in Q2 and 22% in H1 FY27
“The PAT margin for the quarter was 24% and 22% for the first half financial year '27.”
U.S. market: Management agrees a US pick-up would lift margins above current levels
Mukund Kabra · Whole Time Director · Q&A · p. 7
U.S. market: Management agrees a US pick-up would lift margins above current levels
“Yes, that is true.”
Q2 employee cost lower on ESOP reversals and fewer US staff
Beni Rauka · Group Chief Financial Officer · Q&A · p. 11
Q2 employee cost lower on ESOP reversals and fewer US staff
“So because of that, again the ESOP cost has gone down, so payroll cost is also down. So all these factors has impacted us. And apart from that, even in the U.S. also, the payroll cost is slightly lower because of some headcounts.”
Acquisitions and new business
Food: In talks with a few players on partnerships in Food business
Mukund Kabra · Whole Time Director · Q&A · p. 12
Food: In talks with a few players on partnerships in Food business
“We are like talking with a few players to even partner right now, but those are the futuristic things.”
WELLFA: WELLFA B2C business moved into a separate company
Mukund Kabra · Whole Time Director · Q&A · p. 14
WELLFA: WELLFA B2C business moved into a separate company
“Yes, that is where we have separated it from Advanced. We have made a separate company.”
Dividends and buybacks
Buyback completed; 2.41 million equity shares acquired
Mukund Kabra · Whole Time Director · p. 3
Buyback completed; 2.41 million equity shares acquired
“Before we discuss the performance for the quarter, we are pleased to announce that the company has successfully completed the buyback by acquiring 2.41 million equity shares at an average”
Buyback average price INR289.09 per share, via open market
Mukund Kabra · Whole Time Director · p. 4
Buyback average price INR289.09 per share, via open market
“price of INR289.09 per share via open market route. This reflects our continued commitment to enhancing shareholder value and maintaining a balanced approach towards capital allocation.”
One-offs
Q1 increment provision higher by about INR1 crore, reversed in Q2
Beni Rauka · Group Chief Financial Officer · Q&A · p. 11
Q1 increment provision higher by about INR1 crore, reversed in Q2
“I think it was higher by about INR1 crore or so. So the impact of that INR1 crore is the reversal in this particular quarter.”
Sales deferment of about INR10 crore hit Q1; deferment also on higher side in Q2
Mukund Kabra · Whole Time Director · Q&A · p. 8
Sales deferment of about INR10 crore hit Q1; deferment also on higher side in Q2
“Last quarter, we mentioned that deferment was around INR10 crores, which impacted us. This quarter also, the deferment is on a higher side.”
Risks
Global environment described as challenging, with trade and supply chain uncertainty
Mukund Kabra · Whole Time Director · p. 4
Global environment described as challenging, with trade and supply chain uncertainty
“On the global front, the economic environment continues to remain challenging, with geopolitical tensions across various regions creating uncertainty in international trade, supply chains and commodity markets.”
On competition in largest product: players will come and go
Mukund Kabra · Whole Time Director · Q&A · p. 9
On competition in largest product: players will come and go
“The players will come and they will go. You need to stand there, you need to figure out different applications, and that's what we are doing.”
Novonesis Mumbai capex is for bioethanol; company not in that segment
Mukund Kabra · Whole Time Director · Q&A · p. 13
Novonesis Mumbai capex is for bioethanol; company not in that segment
“As of now, if you ask me, we are not present in that segment. So current revenue, I can just say, but you never know, is not going to be affected in any of those areas.”
Other
Q2 revenue INR2,145 million, up 16% year-on-year; H1 revenue up 10%
Mukund Kabra · Whole Time Director · p. 4
Q2 revenue INR2,145 million, up 16% year-on-year; H1 revenue up 10%
“Our top line for the quarter stood at INR2,145 million, registering a growth of 16% year-on-year and 12% on a sequential basis, while the first half of financial year '27 revenue grew by 10% over the corresponding period last year.”
Q2 PAT INR512 million, up 14% from INR447 million
Beni Rauka · Group Chief Financial Officer · p. 5
Q2 PAT INR512 million, up 14% from INR447 million
“Our PAT has increased by INR64 million, a 14% increase from INR447 million to INR512 million.”
Consolidated R&D spend about 4.3% of revenue in Q2, against 3% a year ago
Beni Rauka · Group Chief Financial Officer · p. 7
Consolidated R&D spend about 4.3% of revenue in Q2, against 3% a year ago
“R&D spend, if we consider the intercompany elimination, that works out to be about 4.3% during quarter 2 as compared to 3% in Q2 of FY26.”
Q2 EBITDA INR721 million, up 20% from INR601 million
Beni Rauka · Group Chief Financial Officer · p. 5
Q2 EBITDA INR721 million, up 20% from INR601 million
“Our EBITDA increased by INR121 million, 20% growth from INR601 million to INR721 million, and this is about 34% of our revenue as compared to 33% in the correspond previous quarter.”
Q2 profit before tax INR688 million, up 15% from INR595 million
Beni Rauka · Group Chief Financial Officer · p. 5
Q2 profit before tax INR688 million, up 15% from INR595 million
“Profit before tax increased by INR92 million, a 15% increase from INR595 million to INR688 million.”
Sources
- Earnings call transcript, Q2 FY27 Filed 5 Nov 2026 · 15 pages
Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

